1. Бровкина А.Ф., Вальский В.В., Гусев Г.А. и др. Офтальмоонкология. Руководство для врачей. Под ред. А.Ф.Бровкиной. М.: Медицина, 2002.
2. Гришина Е.Е., Федотова О.Ф., Житенев В.П. Анализ офтальмоонкологоческой патологии у взрослого населения Москвы по данным МОКБ. Сб. научн. трудов "Опухоли и опухолеподобные заболевания органа зрения". М., 1998; 28–31
3. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res 2001; 11: 255–63.
4. Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: Collaborative Ocular Melanoma Study Group Report No.26. Arch Ophthalmol 2005; 123: 1639–43.
5. Diener-West M, Reynolds MS, Agugliaro JD et al. Screening for Metastasis From Choroidal Melanoma: The Collaborative Ocular Melanoma Study Group Report No.23. J Clin Oncol 2004; 22 (12): 2438–44.
6. Albert DM, Niffennegger AS, Willson JKV. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992; 36: 429–38.
7. Leyvraz S, Spataro V, Bauer J et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. Clin Oncol 1997; 15: 2589–95.
8. Зиангирова Г.Г., Лихванцева В.Г. Опухоли сосудистого тракта глаза. М.: Последнее слово, 2003.
9. Pe’er J, Amer R, Kaiserman I. The value of screening tests for metastatic uveal melanoma. Final programme and abstract book 2001; 144.
10. Gombos DS, Van Quill KR, Uusitalo M, O'Brien JM. Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology 2004; 111 (12): 2254–8.
11. Robinson PJ. Imaging liver metastases: current limitations and future prospects. Br J Radiol 73 (867): 234–41.
12. Eskelin S, Pyrhonen S, Summanen P et al. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 1999; 85: 1151–9.
13. Bedikian AY, Legha SS, Mavligit G et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76 (9): 1665–70.
14. Gore RM, Levine MS, Laufer I. Textbook of gastrointestinal radiology. Philadelphia, PA: WB Saunders 1994; 1935.
15. Grainger RG, Allison DJ. Diagnostic radiology: a textbook of medical imaging. New York: Churchill Livingstone, 1998; 1169.
16. Sillaire-Houtmann I, Bonafous J, Veyre A et al. Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma. Fr Ophtalmol 2004; 27 (1): 34–9.
17. Lindholm P, Minn H, Leskinen-Kallio S et al. Influence of the blood glucose concentration on FDG uptake in cancer a PET study. Nucl Med 1993; 34: 1–6.
18. Francken AB, Fulham MJ, Millward MJ, Thompson JF. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Surg Oncol 2006; 32 (7): 780–4.
19. Schoder H, Larson SM, Yeung HWD. PET/computed tomography in oncology integration into clinical management of lymphoma, melanoma and gastrointestinal malignancies. Nucl Med 2004; 45: 72S–81.
20. Cohade C, Osman M, Leal J, Wahl R. Direct comparison of 18 F-FDG PET and PET/CT in patients with colorectal carcinoma./Nucl Med 2003; 44: 1797–803.
21. Eskelin S, Pyrhönen S, Summanen P, Prause JU, Kivelä T. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 1999; 85 (5): 1151–9.
22. Eskelin S, Kivelä T. Imaging to Detect Metastases From Malignant Uveal Melanoma. Arch Ophthalmol 2002; 120: 676.
23. Missotten GS, Korse CM, van Dehn C et al. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol 2007; 28 (2): 63–9.
24. Felberg NT, Shields JA, Maguire J et al. Gamma-glutamyl transpeptidase in the prognosis of patients with uveal malignant melanoma. Am J Ophthalmol 1983; 95 (4): 467–73.
25. Kaiserman I, Amer R. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 2004; 137 (2): 236–43.
26. Callejo SA, Marshall JC, Cools-Lartigue J et al. Macrophage-derived soluble factor enhances melanoma inhibitory activity expression by uveal melanoma cells in vitro. Melanoma Res 2004; 14 (2): 91–5.
27. Reiniger IW, Schaller UC, Haritoglou C et al. Melanoma inhibitory activity (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2005; 243 (11): 1161–6.
28. Schaller UC, Mueller AJ, Bosserhoff AK et al. Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas. Ophthalmologe 2000; 97 (6): 429–32.
29. Schaller UC, Bosserhoff AK, Neubauer AS et al. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res 2002; 12 (6): 593–9.
30. Loppin M, Quillien V, Adamski H et al. Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma. Ann Dermatol Venereol 2007; 134 (6–7): 535–40.
31. Djukanovic D, Hofmann U, Sucker A et al. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20 (3B): 2203–7.
32. Kadkol SS, Lin AY, Barak V et al. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 2006; 47 (3): 802–6.
33. Reiniger IW, Wolf A, Welge-Lüssen U et al. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 2007; 143 (4): 705–7.
34. Barak V, Frenkel S, Kalickman I et al. Serum markers to detect metastatic uveal melanoma. Anticancer Res 2007; 27 (4A): 1897–900.
35. Лихванцева В.Г., Слепова О.С., Бpовкина А.Ф. Интеpфеpоновый статус пpи увеальной меланоме. Вестн. офтальмол. 1999; 115 (6): 35–7.
36. Лихванцева В.Г., Бровкина А.Ф., Слепова О.С. Способ прогнозирования клинического течения увеальной меланомы. Патент Российской Федерации на изобретение RU 2149404 C1, 7 G01N33/53. 05.20.2000. Регистрационный номер заявки: 99106475/14.
37. Гольдман Э.М., Гутенко А.И. Значение лабораторных исследований в прогнозе злокачественной увеальной меланомы. Актуальные вопросы биохимии человека и животных. Сб. статей Казахстанского отделения Всесоюзного биохимического общества, Алма-Ата, 1990; 21–2.
38. Андреева Л.Д., Лихванцева В.Г. Иммуногистохимический анализ апоптоза, интерлейкина-2 и ядерного антигена пролиферации при увеальной меланоме. Опухоли и опухолеподобные заболевания органа зрения. Cб. научных трудов. М., 1998; 10–2.
39. Ren DH, Mayhew E, Hay C et al. Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. Invest Ophthalmol Vis Sci 2004; 45 (4): 1162–8.
40. Слепова О.С. и др. Фактор некроза опухоли-альфа при увеальной меланоме. Офтальмологич. журн. 1998; 5: 357–60.
41. Бровкина А.Ф., Вальский В.В., Зарубей Г.Д. Метастатическое поражение печени у больных с увеальной меланомой. Вестн. офтальмол., 1998; 114 (1): 21–3.
42. Callejo SA, Antecka E, Blanco PL et al. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007; 21 (6): 752–9.
43. Schuster R, Bechrakis NE, Stroux A et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007; 13 (4): 1171–8.
44. Keilholz U, Goldin-Lang P, Bechrakis NE et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 2004; 10 (5): 1605–12.
45. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-Infiltrating Macrophages (CD68+ Cells) and Prognosis in Malignant Uveal Melanoma. Invest Ophthalmol Vis Sci 2001; 42: 1414–21.
46. Niederkorn JY, Wang S. Immunology of intraocular tumors. Ocul Immunol Inflamm 2005; 13 (1): 105–10.
47. Верещагина М.В., Лихванцева В.Г., Анурова О.А. Клинические и иммуногистохимические параллели в диагностике опухолей сосудистого тракта глаза и в прогнозировании неопластического процесса. Автореф. дис. ... канд. мед. наук. М., 2006.
48. Toivonen P, M?kitie T, Kujala E, Kivelä T. Microcirculation and Tumor-Infiltrating Macrophages in Choroidal and Ciliary Body Melanoma and Corresponding Metastases. Invest Ophthalmol Vis Sci 2004; 45: 1–6.
49. Folberg R, Chen X, Boldt HC et al. Microcirculation patterns other than loops and networks in choroidal and ciliary body melanomas. Ophthalmology 2001; 108 (5): 996–1001.
50. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. Natl Cancer Inst 1999; 91 (4): 359–67.
51. Астахова С.Е., Лихванцева В.Г., Ухов Ю.И. и др. Маркеры ангиогенеза в прогнозе увеальной меланомы. Мед. иммунол. 2003; 5 (3–4): 346.
52. Scholes AG, Damato BE, Nunn J et al. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003; 44 (3): 1008–11.
53. Gambrelle J, Labialle S, Dayan G et al. Toward monosomy 3 as the main prognosis factor of uveal melanoma: current cytogenetic data. Fr Ophtalmol 2004; 27: 1061–7.
54. Desjardins L, Levy-Gabriel C, Lumbroso-Lerouic L et al. Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research. Fr Ophtalmol 2006; 29 (7): 741–9.
55. Nareyeck G, Zeschnigk M, Prescher G et al. Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3. Exp Eye Res 2006; 83 (4): 858–64.
56. Tschentscher F, Hüsing J, Hölter T et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63 (10): 2578–84.
57. Maat W, Jordanova ES, van Zelderen-Bhola SL et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies. Arch Pathol Lab 2007; 131 (1): 91–6.
58. Maat W, Long VL, Jordanova ES et al. Monosomy of Chromosome 3 and an Inflammatory Phenotype Occur Together in Uveal Melanoma. Invest Ophthalmol Vis Sci 2008; 49: 505–10.
59. Onken MD, Worley LA, Person E et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res 2007; 13 (10): 2923–7.
60. Häusler T, Stang A, Anastassiou G et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int J Cancer 2005; 116 (6): 909–13.
61. Meir T, Zeschnigk M, Masshöfer L et al. The spatial distribution of monosomy 3 and network vasculogenic mimicry patterns in uveal melanoma. Invest Ophthalmol Vis Sci 2007; 48 (5): 1918–22.
62. Worley LA, Onken MD, Person E et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res 2007; 13 (5): 466–71.
63. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205–9.
64. Tschentscher F, Husing J, Holter T et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 2578–84.
65. Вит В.В., Величко Л.Н., Драгомирецкая Е.И. Возможность прогнозирования клеточного типа увеальных меланом без использования инвазивных методов диагностики. Онкология. 2002; 4 (4): 259–62. 
66. Midena E, Bonaldi L, Parrozzani R et al. Loss ofIn vivo detection of monosomy 3 in eyes with medium-sized uveal melanoma using transscleral fine needle aspiration biopsy. Eur J Ophthalmol 2006; 16 (3): 422–2.

Е.Г.Казимирова, Е.Е.Гришина

Кафедра офтальмологии Российской медицинской академии последипломного образования, Москва